News BMS suffers further setback in lung cancer No fast approval for immunotherapy combo in first line use.
News AZ looks for advantage over Merck in lung cancer trial AZ rejigs endpoints in key trial of durvalumab
News Keytruda set for first line lung cancer use in EU MSD drug will not face competition from BMS rival in this use.
UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
News AZ's Tagrisso shines in lung cancer trial Phase 3 trial supports Tagrisso as "standard of care" for some patients
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
